Company Analysis
Sign in

CytomX Therapeutics, Inc. (CTMX)

Nasdaq: CTMX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2010
Full chart Alerts Compare
Grade4.4
◀ Past 3.4● Present 5.8▶ Future 3.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

86 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to CytomX Therapeutics, Inc.’s names, not what it holds today.

Patents granted
86
86 utility, 1976 to Dec 31, 2025
Granted in 2025
7
Against 10 in 2024 and 6 in 2023
Applications published
142
14 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'10'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals21
Biotechnology20
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CytomX Therapeutics, Inc. its own name
US, as the owner printed on each patent
86 granted
46 published
CytomX Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
96 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,502,439Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofPharmaceuticalsCytomX Therapeutics, Inc.
Dec 16, 202512,498,367Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereofBiotechnologyCytomX Therapeutics, Inc.
Nov 4, 202512,460,017Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofBiotechnologyCytomX Therapeutics, Inc.
Nov 4, 202512,459,999Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofPharmaceuticalsCytomX Therapeutics, Inc.
Oct 14, 202512,441,799Activatable anti-CTLA-4 antibodies and uses thereofPharmaceuticalsCytomX Therapeutics, Inc.
Sep 30, 202512,428,470Compositions containing activatable antibodiesBiotechnologyCytomX Therapeutics, Inc.
Jan 28, 202512,209,120Activatable anti-VEGF scFvBiotechnologyCytomX Therapeutics, Inc.
Nov 12, 202412,139,816Protease-resistant systems for polypeptide display and methods of making and using thereofBiotechnologyCytomX Therapeutics, Inc.
Nov 12, 202412,139,543Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFRPharmaceuticalsCytomX Therapeutics, Inc.
Sep 17, 202412,091,442Activatable cytokine constructs and related compositions and methodsBiotechnologyCytomX Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382351COMPOSITIONS CONTAINING ACTIVATABLE ANTIBODIESBiotechnologyCytomX Therapeutics, Inc.
Oct 30, 20252025/0333539ACTIVATABLE ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES OF THE SAMEBiotechnologyCytomX Therapeutics, Inc.
Oct 30, 20252025/0333487ACTIVATABLE DUAL-ANCHORED MASKED MOLECULES AND METHODS OF USE THEREOFBiotechnologyCytomX Therapeutics, Inc.
Jul 31, 20252025/0243283ACTIVATABLE ANTI-CD3, ANTI-EGFR, HETEROMULTIMERIC BISPECIFIC POLYPEPTIDE COMPLEXBiotechnologyCytomX Therapeutics, Inc.
Jul 17, 20252025/0230239CD3-BINDING PROTEINS AND METHODS OF USE THEREOFBiotechnologyCytomX Therapeutics, Inc.
Jul 3, 20252025/0215110ACTIVATABLE MULTISPECIFIC MOLECULES AND METHODS OF USE THEREOFBiotechnologyCytomX Therapeutics, Inc.
Jul 3, 20252025/0215095PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFBiotechnologyCytomX Therapeutics, Inc.
Jul 3, 20252025/0215094METHOD OF USING AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATABLE ANTIBODY TO DETECT THE PRESENCE OR ABSENCE OF A CLEAVING AGENT AND EGFRPharmaceuticalsCytomX Therapeutics, Inc.
Jul 3, 20252025/0213716PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFPharmaceuticalsCytomX Therapeutics, Inc.
Jun 5, 20252025/0179141ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODSBiotechnologyCytomX Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 15 · Pharmaceuticals 12 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CTMX · research, not advice